Coronary Artery Disease Polygenic Risk Score Identifies Patients at Higher Risk for Recurrent Cardiovascular Events in the CANTOS Trial

Circ Genom Precis Med. 2021 Dec;14(6):e003440. doi: 10.1161/CIRCGEN.121.003440. Epub 2021 Oct 19.

Authors

Huilei Xu^#¹, Claudia Hon^#¹, Sergio Kaiser², Pablo Serrano-Fernandez², Nicole Hartmann², Denise P Yates¹, Margaret Healey¹, Arkady I Gusev¹, Jason M Laramie¹, Scott Kennedy¹, Philippe Marc², Paul M Ridker³, Ma'en Obeidat¹, Michael T Beste¹, Eric C Svensson¹, Aviv Madar¹

Affiliations

¹ Novartis Institutes for Biomedical Research, Cambridge, MA (H.X., C.H., D.P.Y., M.H., A.I.G., J.M.L., S. Kennedy, M.O., M.T.B., E.C.S., A.M.).
² Novartis Institutes for Biomedical Research, Basel, Switzerland (S. Kaiser, P.S.-F., N.H., P.M.).
³ Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.M.R.).

^# Contributed equally.

PMID: 34663088
DOI: 10.1161/CIRCGEN.121.003440

No abstract available

Keywords: atherosclerosis; canakinumab; coronary artery disease; genetics; inflammation; myocardial infarction.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Atherosclerosis*
Clinical Trials as Topic
Coronary Artery Disease* / genetics
Humans
Risk Factors

Substances

Antibodies, Monoclonal, Humanized